Price (delayed)
$0.383
Market cap
$2.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.54
Enterprise value
$788,784
Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against
There are no recent dividends present for OGEN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.